• Takeda Pharmaceutical (NYSE:TAK) has inked a collaboration agreement with privately held Alloy Therapeutics to develop the former's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).
• The companies noted that the paternship will help Alloy develop therapies to treat solid and hematological malignancies.
• A news release noted that iCAR-T "has potential to develop 'off-the-shelf' cell therapies, offering the potential for best-in-class performance with enhanced potency, and significantly lower manufacturing costs compared to autologous cell therapy."
• Terms call for Alloy to receive co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Also, the company wll use its exisiting expertise to advance the iCAR-T/NK platforms and provide broader access to the technology for future partners.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。